Amendments to the Claims:

1. (Currently amended) A composition for local administration of anti-tumor chemotherapeutic to a patient having a tumor, the composition comprising:

a plurality of microspheres incorporating at least one anti-tumor chemotherapeutic; and

a suspending solution comprising at least one apoptosis-inducing chemotherapeutic combined with an amount of a plasma protein effective in increasing the aqueous solubility of the apoptosis-inducing chemotherapeutic in the suspending solution.

2. (Canceled)

3. (Currently amended) The composition of claim ~~2~~ 1, wherein the plasma protein is selected from the group consisting of human serum albumin, γ-immunoglobulin, and combinations thereof.

4. (Previously presented) The composition of claim 1, wherein the longest diameter of the microspheres is less than about 20 microns.

5. (Previously presented) The composition of claim 1, wherein the microspheres are microcapsules.

6. (Previously presented) The composition of claim 1, wherein the anti-tumor chemotherapeutic is contained within the microsphere.

7. (Previously presented) The composition of claim 1, wherein the anti-tumor chemotherapeutic is attached to the microsphere.

8. (Previously presented) The composition of claim 1, wherein the microspheres comprise at least one biodegradable polymer.

9. (Previously presented) The composition of claim 8, wherein the biodegradable polymer is selected from the group consisting of polylactic acid, polyglycolic acid and a co-polymer of polyglycolic and polylactic acid.

10. (Withdrawn) The composition of claim ~~2, wherein~~ the microspheres comprise a non-

biodegradable polymer.

11. (Withdrawn) The composition of claim 2, wherein the non-biodegradable polymer is an ethylene vinyl acetate copolymer.

12. (Previously presented) The composition of claim 2, wherein degradation of the microspheres releases the anti-tumor chemotherapeutic in a therapeutically effective amount.

13. (Original) The composition of claim 12, wherein up to about 50 % of the anti-tumor chemotherapeutic is released from the microspheres within about 24 hours after administration of the microspheres to the patient.

14. (Original) The composition of claim 12, wherein between about 15 to about 25 % of the anti-tumor chemotherapeutic is released from the microspheres within about 24 hours after administration of the microspheres to the patient.

15. (Previously amended) The composition of claim 12, wherein the anti-tumor chemotherapeutic is released from the microsphere by diffusion.

16. (Original) The composition of claim 15, wherein the anti-tumor chemotherapeutic is released in a therapeutically effective amount over a period of time from about 1 week to about six months after administration to the patient.

17. (Original) The composition of claim 15, wherein the anti-tumor chemotherapeutic is released in a therapeutically effective amount over a period of time from about 3 weeks to about 2 months after administration to the patient.

18. (Previously presented) The composition of claim 1, wherein the anti-tumor chemotherapeutic comprises at least one apoptosis inducing chemotherapeutic.

19. (Withdrawn) The composition of claim 18, wherein the apoptosis inducing chemotherapeutic is selected from the group consisting of cisplatin, adriamycin, butyric acid, cyclophosphamide, etoposide, amsacrine, genistein, and mitoguazone.

20. (Previously presented) The composition of claim 18, wherein the microspheres comprise paclitaxel.

21. (Original) The composition of claim 20, wherein the paclitaxel is at a concentration from about 0.1 to about 10 mg/mL.

22. (Original) The composition of claim 20, wherein the paclitaxel is at a concentration from about 0.5 to about 5 mg/mL.

23. (Canceled)

24. (Previously presented) The composition of claim 1, wherein the suspending solution contains paclitaxel.

25. (Previously presented) The composition of claim 24, wherein the total paclitaxel in the composition is about 70 to about 280 mg.

26. (Original) The composition of claim 24, wherein the paclitaxel in both the microspheres and in the solution is at a concentration of about 135 mg/m^2 to about 175 mg/m^2.

27. (Previously presented) The composition of claim 24, wherein about 10 % to about 90 % of the paclitaxel is incorporated in the microspheres.

28. (Previously presented) The composition of claim 27, wherein about 60 % to about 90 % of the paclitaxel is incorporated in the microspheres.

29. (Previously presented) The composition of claim 28, wherein about 80 % to about 90 % of the paclitaxel is incorporated in the microspheres.

30. (Canceled)

31. (Canceled)

32. (Previously presented) The composition of claim 24, wherein the suspending solution comprises an anti-tumor chemotherapeutic selected from the group consisting of paclitaxel, cisplatin, adriamycin, butyric acid, cyclophosphamide, etoposide, amsacrine, genistein, and mitoguazone.

33. (Currently amended) A method for local administration of an anti-tumor chemotherapeutic to a tumor, comprising the steps of:

delivering to a tumor a chemotherapeutic reservoir comprising (1) a plurality of microspheres incorporating at least one anti-tumor chemotherapeutic and (2) a

suspending solution comprising at least one apoptosis-inducing chemotherapeutic combined with an amount of a plasma protein effective in increasing the aqueous solubility of the apoptosis-inducing chemotherapeutic in the suspending solution.

34. (Canceled)

35. (Currently amended) The method of claim ~~34~~ 33, wherein the plasma protein is selected from the group consisting of human serum albumin, γ-immunoglobulin, and combinations thereof.

36. (Previously presented) The method of claim 33, wherein the microspheres comprise at least one biodegradable polymer.

37. (Previously presented) The method of claim 36, wherein the biodegradable polymer is selected from the group consisting of polylactic acid, polyglycolic acid and a co-polymer of polyglycolic and polylactic acid.

38. (Withdrawn) The method of claim 34, wherein the microspheres comprise a non-biodegradable polymer.

39. (Withdrawn) The method of claim 38, wherein the non-biodegradable polymer is a ethylene-vinyl acetate copolymer.

40. (Previously presented) The method of claim 33, wherein the anti-tumor chemotherapeutic is released from the microspheres in a therapeutically effective amount primarily by degradation of the microspheres.

41. (Previously presented) The method of claim 40, wherein about 50 % of the anti-tumor chemotherapeutic is released from the microspheres within about 24 hours following delivery of the chemotherapeutic reservoir to the tumor.

42. (Previously presented) The method of claim 40, wherein about 15 to about 25 % of the anti-tumor chemotherapeutic is released from the microspheres within about 24 hours following delivery of the chemotherapeutic reservoir to the tumor.

43. (Previously presented) The method of claim 34, wherein the anti-tumor chemotherapeutic is released from the microsphere primarily by diffusion.

44. (Original) The method of claim 43, wherein the anti-tumor chemotherapeutic is continuously released from the microspheres in a therapeutically effective amount for a time period lasting from between about one week to about six months.

45. (Original) The method of claim 43, wherein the anti-tumor chemotherapeutic is continuously released from the microspheres in a therapeutically effective amount for a time period lasting from between about three weeks to about two months.

46. (Previously presented) The method of claim 33, wherein the longest diameter of the microspheres are less than about 20 microns.

47. (Previously presented) The method of claim 33, wherein the microspheres are microcapsules.

48. (Previously presented) The method of claim 33, wherein the microspheres comprise at least one apoptosis inducing chemotherapeutic.

49. (Withdrawn) The method of claim 48, wherein the apoptosis inducing chemotherapeutic is selected from the group consisting of cisplatin, adriamycin, butyric acid, cyclophosphamide, etoposide, amsacrine, genistein, and mitoguazone.

50. (Previously presented) The method of claim 48, wherein the microspheres comprise paclitaxel.

51. (Original) The composition of claim 50, wherein the paclitaxel is at a concentration from about 0.1 to about 10 mg/mL.

52. (Original) The method of claim 50, wherein the paclitaxel is at a concentration from about 0.5 to about 5 mg/mL.

53. (Canceled)

54. (Previously presented) The method of claim 33, wherein the suspending solution contains paclitaxel.

55. (Previously presented) The method of claim 33, wherein the total paclitaxel in the composition is about 70 to about 280 mg.

56. (Previously presented) The method of claim 33, wherein the total paclitaxel in both the

microspheres and in the solution is at a concentration of about 135 mg/m^2 to about 175 mg/m^2.

57. (Previously presented) The method of claim 33, wherein the composition contains paclitaxel, about 10 % to about 90 % of which is incorporated in the microspheres.

58. (Previously presented) The method of claim 33, wherein about 60 % to about 90 % of the paclitaxel is incorporated in the microspheres.

59. (Previously presented) The method of claim 33, wherein about 80 % to about 90 % of the paclitaxel is incorporated in the microspheres.

60. (Canceled)

61. (Canceled)

62. (Previously presented) The method of claim 33, wherein the suspending solution comprises an anti-tumor chemotherapeutic selected from the group consisting of paclitaxel, cisplatin, adriamycin, butyric acid, cyclophosphamide, etoposide, amsacrine, genistein, and mitoguazone.

63. (Previously presented) The method of claim 33, wherein the delivering step includes the step of positioning the chemotherapeutic reservoir within the tumor.

64. (Previously presented) The method of claim 33, wherein the delivering step includes the step of intratumorally injecting the chemotherapeutic reservoir within the tumor.

65. (Previously presented) The method of claim 33, wherein the delivering step includes the step of positioning chemotherapeutic reservoir adjacent to the tumor.

66. (Previously presented) The method of claim 33, wherein the chemotherapeutic reservoir is delivered into the tumor with elevated pressure.

67. (Previously presented) The method of claim 33, further comprising a step of delivering to the tumor a solution comprising a chemotherapeutic before the step of delivering the chemotherapeutic reservoir.

68. (Previously presented) The method of claim 67, wherein the chemotherapeutic comprises paclitaxel.

69. (Previously presented) The method of claim 67, wherein both the solution and the chemotherapeutic reservoir are delivered with elevated pressure.

70. (Currently amended) The method of claim ~~34~~ 33, wherein the plasma protein is human serum albumin.

71. (Currently amended) The method of claim ~~2~~ 1, wherein the plasma protein is human serum albumin.